Trial Design for Mold-Active Agents: Time to Break the Mold--Aspergillosis in Neutropenic Adults
Open Access
- 15 May 2007
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 44 (10), 1298-1306
- https://doi.org/10.1086/514352
Abstract
No abstract availableThis publication has 71 references indexed in Scilit:
- Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)Clinical Infectious Diseases, 2007
- Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host DiseaseNew England Journal of Medicine, 2007
- Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with NeutropeniaNew England Journal of Medicine, 2007
- Prophylaxis and Aspergillosis — Has the Principle Been Proven?New England Journal of Medicine, 2007
- Multidimensional Volumetric Imaging of Pulmonary Infiltrates for Measuring Therapeutic Response to Antifungal Therapy in Experimental Invasive Pulmonary AspergillosisAntimicrobial Agents and Chemotherapy, 2006
- Aspergillose pulmonaire invasive compliquant un choc septiqueRevue des Maladies Respiratoires, 2005
- Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 2004
- A Double‐Blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised PatientsClinical Infectious Diseases, 2002
- Kappa coefficients in medical researchStatistics in Medicine, 2002
- Aspergillus tracheobronchitis after allogeneic bone marrow transplantationBone Marrow Transplantation, 1999